Active	Status	Sponsor type	Region	Phase	Filter
2 Active 3 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Conte, PierFranco
A-Brave, NCT02926196 / 2016-000189-45: Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab Apr 2021 - Sep 2021 : From A-Brave trial	Active, not recruiting	3	474	Europe	MSB0010718C, Avelumab	Istituto Oncologico Veneto IRCCS, University of Padova, Dipartimento di scienze chirurgiche, Oncologiche e Gastroenterologiche	Triple Negative Breast Neoplasms	06/24	10/25
NCT03763604: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer	Available	N/A		Europe, Canada, RoW	Abemaciclib, LY2835219	Eli Lilly and Company	Metastatic Breast Cancer